{"ticker": {"uuid": "c14343c1-3209-4cb8-8950-333ee2fb80c8", "symbol": "2575", "name": "Xuanzhu Biopharmaceutical Co., Ltd.", "exchange": "HKG", "country": "HK", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Xuanzhu shares dip despite phase III ALK inhibitor data", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQNVllR0w2c1VXUmRxS3plRWF1Rll5ekNMMEE4bHZZYklBQlZiSS1OVTl6SHRxZzViVmtLNkRER2NIN1BUR3BSY2lWQ1VSbzF2Z3BIT1lnazI1aTgyUFB5b2doT3lwSWtnV25TbU5WNmdOOTZSNnF1ajgzNHVERjd4TTFnTVlkS1E2UVladUxrR3dlNzRraHpGdlE2eDQ?oc=5", "source_name": "BioWorld News", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Boston Oncology in cancer drug deal with China's Xuanzhu Biopharmaceutical", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPMjlJd3FsNGI5aE9MSWJJYlRnVjdrV1ZrYlMtbV9xSzBTRjZsSG1wRzdNNVRvbHN1amFnUzkyczNpODY5MkdfVFJmR2U0MjFaUVNJV2RqVkNyeW5Ld3JlenFfR2tDNzNKTHdkTlZ2YkRZTFBzdXk5ZERlYV9yQmhvWGlQeXNQTk9vbHYtbWxfT3QzV3FZZlJDc3lDeUpwMmVBU0VCRTFYMmdOZldFYzFnVHc1clZTUnVZNXNrc2EtUEY?oc=5", "source_name": "Reuters", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xuanzhu and SignalChem Lifesciences Announce Licensing Agreement for SLC-391 in Greater China", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxNaGItdHR6M0ZsenFjSFlabG96UjFma0FXNlRYcVRPNmdNREdwc2ZGOXY3YjZ5ZFlTMXBNS3d2VGNPbG1GOGFDWllGckwtcDA3bktFVE91YVdHRGQ4dlNmZFpXN3Z5UW9rOUI3V00tcXlVWTdmaUtrWUdhbzhFTHRScEFoUnhFU1RqQmg3N21RYjhZTUo2UGZleGJyUlppREhHV1hCVzI3V0tVOG9xSHV5S3pIaVBITW5BRldhYjJsZl9wRk9wM2F5bE5pWUJPNVdLY0E?oc=5", "source_name": "Issuewire", "published_at": "2021-09-24T07:00:00+00:00", "published_display": "24 Sep 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Xuanzhu shares dip despite phase III ALK inhibitor data", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQNVllR0w2c1VXUmRxS3plRWF1Rll5ekNMMEE4bHZZYklBQlZiSS1OVTl6SHRxZzViVmtLNkRER2NIN1BUR3BSY2lWQ1VSbzF2Z3BIT1lnazI1aTgyUFB5b2doT3lwSWtnV25TbU5WNmdOOTZSNnF1ajgzNHVERjd4TTFnTVlkS1E2UVladUxrR3dlNzRraHpGdlE2eDQ?oc=5", "source_name": "BioWorld News", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Boston Oncology in cancer drug deal with China's Xuanzhu Biopharmaceutical", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPMjlJd3FsNGI5aE9MSWJJYlRnVjdrV1ZrYlMtbV9xSzBTRjZsSG1wRzdNNVRvbHN1amFnUzkyczNpODY5MkdfVFJmR2U0MjFaUVNJV2RqVkNyeW5Ld3JlenFfR2tDNzNKTHdkTlZ2YkRZTFBzdXk5ZERlYV9yQmhvWGlQeXNQTk9vbHYtbWxfT3QzV3FZZlJDc3lDeUpwMmVBU0VCRTFYMmdOZldFYzFnVHc1clZTUnVZNXNrc2EtUEY?oc=5", "source_name": "Reuters", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xuanzhu and SignalChem Lifesciences Announce Licensing Agreement for SLC-391 in Greater China", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxNaGItdHR6M0ZsenFjSFlabG96UjFma0FXNlRYcVRPNmdNREdwc2ZGOXY3YjZ5ZFlTMXBNS3d2VGNPbG1GOGFDWllGckwtcDA3bktFVE91YVdHRGQ4dlNmZFpXN3Z5UW9rOUI3V00tcXlVWTdmaUtrWUdhbzhFTHRScEFoUnhFU1RqQmg3N21RYjhZTUo2UGZleGJyUlppREhHV1hCVzI3V0tVOG9xSHV5S3pIaVBITW5BRldhYjJsZl9wRk9wM2F5bE5pWUJPNVdLY0E?oc=5", "source_name": "Issuewire", "published_at": "2021-09-24T07:00:00+00:00", "published_display": "24 Sep 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 60, "total_relevant": 3, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 3, "score": 50, "total": 3, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 62, "events": [{"event": "general", "label": "Market update", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.9, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 12.88, "latest_week": "2026-07-10", "one_week_move": -9.6, "four_week_move": -20.6, "twelve_week_move": -61.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.010689, "market_dynamics_buy_signal": false, "relative_strength": null, "fair_value_gap": -71.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 34.9315, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-9.6% over one week, -20.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 52, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "BioWorld News", "count": 1}, {"label": "Reuters", "count": 1}, {"label": "Issuewire", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 3}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "62/100 classification confidence."}, {"label": "Company focus", "value": "3", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-9.6% over one week, -20.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Xuanzhu shares dip despite phase III ALK inhibitor data"}], "updated_at": "2026-07-18T01:55:47.762067+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}